IOMINVESTCOM
07 Dec 2017
Gene editing research Benchmark Holdings plc ("Benchmark" or the "Company"
Benchmark participates in gene editing research to develop disease resistance in salmonBenchmark, the aquaculture health, nutrition, and genetics business, is pleased to announce its participation in an important gene editing research project. · Third party funded study to investigate the potential for gene editing technology to increase resistance against infectious salmon anaemia (ISA)· Gene editing represents a significant long-term opportunity in animal health, following on from recent breakthroughs in human health · First of a number of initiatives being undertaken by Benchmark in this field for wider applications The study, funded by a £500,000 Industrial Partnership Award from the UK's Biotechnology and Biological Sciences Research Council (BBSRC), will last three years and will investigate the possible use of gene editing technology to increase resistance against ISA. Project collaborators include individuals from the Roslin Institute, the University of Aberdeen, Benchmark's SalmoBreed, the Institute of Marine Research (Norway), INRA (France), Marine Science Scotland (Aberdeen) and Cefas (UK). The aim of the study is to identify genes involved in the infection of Atlantic salmon by ISA and make alterations to increase resistance. This could then be applied to produce ISA resistant broodstock for farming. Gene editing is a new technology which uses enzyme systems such as CRISPR/Cas9 and TALEN amongst others to make precise, targeted alterations to the DNA sequence. In contrast with previous technologies it does not rely on introduction of genes from other species. ISA causes high mortality and significant monetary losses in affected salmon farms worldwide, and is a major welfare issue. There are no treatments for ISA and, in the event of an outbreak, producers are forced to cull all affected stock. Existing solutions such as vaccination and biosecurity cannot fully prevent the spread of the disease. Gene editing can provide an additional way to combat ISA. This study is the first of a number of initiatives being undertaken by Benchmark in this field. Gene editing represents a significant long-term opportunity, and learnings from this study will be applied to other disease areas and species including shrimp and tilapia. Malcolm Pye, Benchmark CEO, commented: "Gene editing is a potentially powerful tool to combat disease in aquaculture and, with a team of world class geneticists, Benchmark is at the forefront of this research in line with our strategy of developing world class aquaculture health products. This is a very exciting time for gene editing with major breakthroughs in human health resulting from decades of research which augur well for animal health. We are delighted to be collaborating with leading institutions to use this novel technology to improve the health and welfare of farmed fish." Enquiries Benchmark Holdings plc Malcolm Pye, CEOIvonne Cantu, Investor Relations DirectorRachel Aninakwah, Communications
IOMINVESTCOM
05 Dec 2017
Trading Update and Notice of Results 5 December 2017Information within this announcement is deemed by the Company to constitute inside information under the Market Abuse Regulations (EU) No. 596/2014.Benchmark Holdings plc("Benchmark", the "Company" or the "Group"Trading Update and Notice of ResultsBenchmark, the aquaculture health, nutrition, and genetics business, provides the following trading update further to the announcement issued on 8 September 2017.Financial Highlights -- Revenues of GBP138m, in line with market expectations (unaudited) -- Adjusted EBITDA of GBP10m (unaudited), ahead of the Company's guidance of GBP8.7m-GBP9.3m provided in the announcement of 8 September-- Improved result from previous guidance driven by positive trading in Genetics and Advanced Nutrition, and lower bonus accruals, partially offset by forex movements, Animal Health and lumpfish sales -- Net debt at year end of GBP24m Divisional HighlightsAdvanced Nutrition-- Overall, like for like revenues for the division grew by 21% (or by 8% on a constant currency basis over the prior year). Continued signs of recovery in key shrimp markets resulting in strong growth in sales of compound hatchery diets and health products, with Artemia sales similar to last yearGenetics-- Strong sales growth with a 49% increase (up 23% on a constant currency basis), driven by increasing demand for salmon products with sales in salmon eggs up on prior year in every major marketAnimal Health (medicines and vaccines)-- Continued progress in pipeline of 46 products, of which five are in regulatory phase, and ten are in pre-regulatory development trialsNotice of ResultsBenchmark will announce its full year results for the year ended 30 September 2017 on Tuesday 23 January 2018. An analyst meeting will be held on that day at 9.30am at the offices of MHP Communications, 6 Agar Street, London WC2N 4HN. To register your interest, please contact [email protected] Pye, CEO, commented"Benchmark has delivered organic growth and has achieved significant operational milestones, whilst continuing to invest in the development of its pipeline and infrastructure despite the challenges faced through the year. These, together, position us as a leader in one of the fastest growing segments in the food industry with great opportunities for further robust growth in the future."-ENDS-
estiente
01 Dec 2017
Other news Positive news on BMKs website. All good Information to indicate future prospects.[link] see this being a great long term share, with many things planned to address growing market requirements.Good luck to all.
IOMINVESTCOM
25 Nov 2017
Re: Topped up on a few more this am Good write-up this weekend on these in SCSW which goes into great detail of all divisions now created over the last few years to build a great business going forward. atb
IOMINVESTCOM
08 Nov 2017
Topped up on a few more this am Based on this morning's news and the positive comments coming from SCSW early this month decided to average down on buying a few more.atb
equity_dev
23 Jun 2017
Results webinar: Thursday 29th June at 11.45am We will be hosting a results webinar with the management of Benchmark Holdings.The presentation will last around 30mins with time afterwards for Q&A. If you would like to send questions in ahead of the webinar please send them to [email protected] register for free and find out more please visit: [link]
IOMINVESTCOM
26 Apr 2017
Nice SP gain today. Wonder whether it will get a mention in this Saturday's SCSWatb
equity_dev
17 Jan 2017
Hear management present If you would like to hear management present results for the year ended 30 September 2016 on behalf of Benchmark Holdings we will be hosting a webinar on Thursday January 26th at 11.45am. Malcolm Pye, CEO, and Mark Plampin, Chief Financial Officer, will give a presentation lasting approximately 30 mins and there will then be an opportunity for Q&A.To join please register at: [link] you would like to submit any questions for management ahead of the meeting please send them to [email protected] regards,The Equity Development Team
IOMINVESTCOM
18 Nov 2016
Good performance last few days After flat-lining in that 63 / 66 range it's good to see the last few days gains which is now above the 200 ema.Long may it continue!!GLTA
equity_dev
14 Sep 2016
Meet with management If you would like to hear Malcolm Pye, Chief Executive Officer, provide an update on Benchmark he will be presenting at our next investor forum on the evening of Wednesday 28th of September. Also appearing will be the management of Venture Life Group plc and Vp plc. To learn more about the forum and to register for free please follow this link: [link] Equity Development team
IOMINVESTCOM
10 Aug 2015
Re: Midas Sunday Share tip [link]
IOMINVESTCOM
10 Aug 2015
Re: Midas Sunday Share tip [link]
IOMINVESTCOM
10 Aug 2015
Midas Sunday Share tip [link]
gamesinvestor
01 Jun 2015
Re: Paul Scott's view IOM -- Is it any wonder this company is considered complicated :-They have no less than 30 people on the board or as directors. This for a company that turns over £35M and is increasing it's losses.Any sensible person running this business would conclude that 1/3 rd of this number is more than adequate and unless they start to restructure and get their cost base down radically, they could be in a much worse situation.Games -- Some businesses grow by finding roles for their friends and acquaintances, where in actual fact no role is needed -- this looks like one of those.
IOMINVESTCOM
06 May 2015
Re: Oh Dear now 18%
